Literature DB >> 6788567

Evaluation of the roles of lipoprotein lipase and hepatic lipase in lipoprotein metabolism: in vivo and in vitro studies in man.

A Nicoll, B Lewis.   

Abstract

The roles of lipoprotein lipase (LPL) and hepatic lipase in very low density lipoprotein (VLDL) and VLDL remnant metabolism were investigated by (1) in vivo studies where the kinetics of VLDL-apo B removal were measured in patients with non-functioning lipoprotein lipase systems, and (2) in vitro studies where the relative capacities of hepatic lipase and LPL to hydrolyse the triglyceride (TG) of different lipoprotein substrates was measured. The results indicated that VLDL-apo B removal was not impaired in patients with non-functional LPL, nor ws there any apparent abnormality in the conversion of VLDL-apo B to intermediate- (IDL) and low (LDL) density lipoprotein-apo B. Post-heparin plasma hepatic lipase activity against VLDL was normal in these subjects. Purified normal hepatic lipase had a similar Km for VLDL-TG hydrolysis (1.57 mmol/l) to that of LPL (1.49 mmol/l). However, at equal lipoprotein TG concentration, hepatic lipase had increasing activity with lipoproteins of decreasing particle size, in the order chylomicrons much less than VLDL of Sf 100-400 less than VLDL of Sf 60-100 less than VLDL of Sf 20-60 less than IDL. The mean contribution of hepatic lipase to VLDL-TG hydrolysis by post-heparin plasma was 35% in normal controls, but the contribution to IDL-TG hydrolysis was significantly higher (mean - 58%). It is concluded that hepatic lipase plays a significant role in VLDL and, especially, IDL metabolism, at least in patients with non-functioning lipoprotein lipase.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6788567     DOI: 10.1111/j.1365-2362.1980.tb02090.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  19 in total

1.  Effects of combined estrogen and progestin administration on plasma lipoprotein metabolism in postmenopausal women.

Authors:  B M Wolfe; M W Huff
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

2.  Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects.

Authors:  J Shepherd; C J Packard; J M Stewart; R F Atmeh; R S Clark; D E Boag; K Carr; A R Lorimer; D Ballantyne; H G Morgan
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

3.  Effect of heparin-induced lipolysis on the distribution of apolipoprotein e among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase.

Authors:  A Rubinstein; J C Gibson; J R Paterniti; G Kakis; A Little; H N Ginsberg; W V Brown
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

4.  Influence of lysophosphatidylcholine on the C-apolipoprotein content of rat and human triglyceride-rich lipoproteins during triglyceride hydrolysis.

Authors:  E E Windler; S Preyer; H Greten
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

5.  Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil.

Authors:  M S Weintraub; S Eisenberg; J L Breslow
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

6.  Chylomicron-retinyl palmitate clearance in type I hyperlipidemic families.

Authors:  D L Sprecher; S L Knauer; D M Black; L A Kaplan; A A Akeson; M Dusing; D Lattier; E A Stein; M Rymaszewski; D A Wiginton
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

7.  Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in normal and lipoprotein lipase-deficient humans.

Authors:  A F Stalenhoef; M J Malloy; J P Kane; R J Havel
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

8.  Lipoprotein metabolism during acute inhibition of lipoprotein lipase in the cynomolgus monkey.

Authors:  I J Goldberg; N A Le; H N Ginsberg; R M Krauss; F T Lindgren
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

9.  Abnormal distribution of VLDL subfractions in type 1 (insulin-dependent) diabetic patients: could plasma lipase activities play a role?

Authors:  L Patti; G Romano; L Di Marino; G Annuzzi; M Mancini; G Riccardi; A A Rivellese
Journal:  Diabetologia       Date:  1993-02       Impact factor: 10.122

10.  Lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase in the cynomolgus monkey.

Authors:  I J Goldberg; N A Le; J R Paterniti; H N Ginsberg; F T Lindgren; W V Brown
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.